Bioresorbable vascular scaffolds to treat coronary allograft vasculopathy: Insights from optical coherence tomography imaging
Cardiac allograft vasculopathy (CAV) constitutes a major impediment in long-term survival after heart transplantation (HTx). Nowadays, percutaneous coronary intervention for CAV is attempted when significant, focal stenosis has developed, notwithstanding the lack of evidence for survival benefit over medical therapy. The advent of new-generation drug-eluting stents (DESs) did not reduce in-stent restenosis rates compared with first-generation DESs. 1 Therefore, there is still a need for improvements in revascularization strategies for CAV.